A Phase III randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine ("Ice") dependence

米氮平作为甲基苯丙胺（“冰毒”）依赖药物疗法的 III 期随机安慰剂对照试验

• 批准号: nhmrc : 2000375
• 金额: $ 392.3万
• 依托单位国家: 澳大利亚
• 项目类别: Clinical Trials and Cohort Studies Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/a-phase-iii-ice-dependence/1780893
• 关键词: Phase; III; randomised; placebo; controlled

Crystalline methamphetamine ('ice') is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug. This clinical trial will examine whether mirtazapine, a newly identified treatment agent for methamphetamine use, can be used safely and effectively in routine clinical care to manage methamphetamine dependence in Australia.

结晶甲基苯丙胺（“冰”）在澳大利亚日益受到关注。没有批准的药物可用于治疗对这种药物的依赖。这项临床试验将研究米氮平，一种新发现的甲基苯丙胺使用治疗剂，是否可以安全有效地用于常规临床护理，以管理澳大利亚的甲基苯丙胺依赖。